Neuland Laboratories Reports Strong Q4FY26 Results; PAT Jumps 665%, Announces Rs 34 Dividend

The Indian equity markets ended lower on Tuesday, with the benchmark Nifty 50 index declining 1.83 per cent to close at 23,379.55. Selling pressure remained visible across pharmaceutical and healthcare stocks during the session. In this segment, Neuland Laboratories remained in focus after the company announced its Q4FY26 and FY26 consolidated financial results along with a final Dividend recommendation and capacity expansion plans. On Tuesday, Neuland Laboratories share price declined 3.12 per cent to Rs 17,003.00.

Neuland Laboratories Q4FY26 Results

Neuland Laboratories reported consolidated revenue from operations of Rs 776.25 crore in Q4FY26 as against Rs 328.36 crore reported in Q4FY25, registering a sharp growth of 136.3 per cent YoY. Total income for the quarter stood at Rs 788.71 crore compared to Rs 335.82 crore in the corresponding quarter previous year.

Profit before Tax came in at Rs 287.49 crore during Q4FY26 as against Rs 39.30 crore reported in Q4FY25, reflecting a growth of 631.5 per cent YoY. Profit after tax stood at Rs 212.67 crore in Q4FY26 compared to Rs 27.81 crore reported in the corresponding quarter last year, registering a sharp growth of 664.7 per cent YoY. Earnings per share for the quarter stood at Rs 165.76 compared to Rs 21.67 reported in Q4FY25.

Neuland Laboratories FY26 Annual Performance

For the financial year ended March 31, 2026, Neuland Laboratories reported consolidated revenue from operations of Rs 2,022.99 crore as against Rs 1,476.84 crore reported in FY25, registering a growth of 37 per cent YoY. Total income for FY26 stood at Rs 2,053.15 crore compared to Rs 1,497.35 crore in FY25.

Profit before tax came in at Rs 488.98 crore during FY26 as against Rs 346.33 crore reported in FY25, reflecting a growth of 41.2 per cent YoY. Profit after tax stood at Rs 364 crore in FY26 compared to Rs 260.11 crore reported in the previous financial year, registering a growth of 39.9 per cent YoY. Earnings per share for FY26 stood at Rs 283.71 compared to Rs 202.74 in FY25.

Dividend Announcement

The Board of Directors recommended a final dividend of Rs 34 per equity share having face value of Rs 10 each for FY26, subject to shareholder approval at the upcoming Annual General Meeting. The company fixed July 24, 2026 as the record date for determining shareholder eligibility for the dividend.

Capacity Expansion Plan

Neuland Laboratories approved capacity enhancement at its Unit-1 facility located in Bonthapally Village, Telangana. The company plans to add 120.5 KL capacity over the next 12 to 18 months with an investment of around Rs 143.4 crore funded through internal accruals and borrowings. The expansion is aimed at catering to growing customer demand.

Geographical Revenue Performance

During Q4FY26, the company reported strong traction across key international markets. Revenue from the USA and North America stood at Rs 313.66 crore, while Europe contributed Rs 296.61 crore during the quarter. India revenue came in at Rs 121.50 crore.

Other Developments

The Board also approved the appointment of Dr. Mauricio Futran as an Additional Director categorized as Non-Executive Non-Independent Director with effect from May 12, 2026. Dr. Futran brings over 40 years of experience in process development, manufacturing and operational excellence across global pharmaceutical companies.

About Neuland Laboratories

Neuland Laboratories Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs) and provides allied services to pharmaceutical companies globally. The company operates across custom manufacturing solutions and generic drug substances catering to regulated and emerging markets.

The company has wholly owned subsidiaries in the United States and Japan and exports pharmaceutical products to markets including North America, Europe and other international regions.

Share your views on Neuland Laboratories’ Q4FY26 performance and expansion plans in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.